Senseonics: Eversense 365 Receives FDA Clearance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Nasdaq notches record high close as investors focus on earnings
BTIG Reiterates Neutral Rating on Senseonics Holdings (SENS)
September 17, 2024 8:35 AM EDTBTIG analyst Marie Thibault reiterated a Neutral rating on Senseonics Holdings (NYSE: SENS).
The analyst comments "This morning, Senseonics announced that they received FDA clearance for the 365-day Eversense continuous glucose monitoring (CGM) system. The 365-day system is indicated for adults with Type 1 and Type 2 diabetes and... More
Stifel Reiterates Buy Rating on Senseonics Holdings (SENS)
September 17, 2024 8:29 AM EDTStifel analyst Mathew Blackman reiterated a Buy rating and $2.50 price target on Senseonics Holdings (NYSE: SENS).
The analyst comments "This morning, SENS announced on-time FDA approval of Eversense 365-day with iCGM status; a 4Q24 US launch timeline was also re-affirmed. Importantly, approval... More



